VX-745 , ≥98% , 209410-46-8
CAS NO.：209410-46-8
Empirical Formula: C19H9Cl2F2N3OS
Molecular Weight: 436.26
MDL number: MFCD09834070
| Pack Size | Price | Stock | Quantity |
| 10MG | RMB615.20 | In Stock |
|
| 25mg | RMB1271.20 | In Stock |
|
| 50MG | RMB1914.40 | In Stock |
|
| 100mg | RMB3671.20 | In Stock |
|
| 250mg | RMB7999.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 261-264 °C |
| Boiling point: | 578.9±60.0 °C(Predicted) |
| Density | 1.55±0.1 g/cm3(Predicted) |
| storage temp. | -20°C |
| solubility | ≥21.8 mg/mL in DMSO; insoluble in H2O; ≥2.1 mg/mL in EtOH with gentle warming and ultrasonic |
| pka | -0.97±0.40(Predicted) |
| form | powder |
| color | white to beige |
| InChI | 1S/C19H9Cl2F2N3OS/c20-11-2-1-3-12(21)17(11)18-14-5-7-16(25-26(14)9-24-19(18)27)28-15-6-4-10(22)8-13(15)23/h1-9H |
| InChIKey | VEPKQEUBKLEPRA-UHFFFAOYSA-N |
| SMILES | FC1=C(SC2=NN(C=N3)C(C=C2)=C(C4=C(Cl)C=CC=C4Cl)C3=O)C=CC(F)=C1 |
Description and Uses
VX-745 is an inhibitor of p38α MAPK (IC50 = 9 nM). It is selective for p38α over p38β MAPK (Ki = 220 nM) as well as ERK, JNK, and a panel of 50 kinases when used at a concentration of 2 μM. VX-745 inhibits LPS-induced production of IL-1β and TNF-α in isolated human peripheral blood mononuclear cells (PBMCs; IC50s = 45 and 51 nM, respectively). It reduces disease severity in a type II collagen-induced mouse model of arthritis when administered at a dose of 10 mg/kg.
VX 745 is a potent and selective inhibitor of p38α mitogen-activated protein (MAP) kinase. VX 745 is a potential anti-inflammatory agents. Studies suggest that VX 745 may be useful in the treatment of Werner syndrome.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H332-H335 |
| Precautionary statements | P261-P280-P305+P351+P338 |
| WGK Germany | WGK 3 |
| HS Code | 2933599590 |
| Storage Class | 11 - Combustible Solids |
